Notice of RetractionSerum Insulin like Growth Factor - 1 as a Reliable Diagnostic Marker: Myanmar Postmenopausal Osteoporotic Study

Notice of Retraction

After careful and considered review of the content of this paper by a duly constituted expert committee, this paper has been found to be in violation of IEEE´s Publication Principles.

We hereby retract the content of this paper. Reasonable effort should be made to remove all past references to this paper.

The presenting author of this paper has the option to appeal this decision by contacting TPII@ieee.org.

Insulin like growth factors- 1 (IGF- 1) is essential for longitudinal bone growth, as it stimulates proliferation and differentiation of chondrocytes in the epiphyseal plate. The aim of this study is to measure the serum IGF-1 level and predict as reliable marker in postmenopausal osteoporotic women. Serum IGF-1 level of 50 postmenopausal osteoporotic women (≥ 50 years ) with bone mineral density (BMD) (T score ≤ - 2.5) and that of 60 postmenopausal non osteoporotic women (≥ 50 years) with BMD (T score >; -1) were measured by ELISA method. Serum IGF-1 level of postmenopausal osteoporotic women (211.24 ± 36.30 ng/ml) was significantly lower than that of non osteoporotic women (- 365.15 ± 23.55 ng/ml) at p<;0.05*.BMD (Tscore) of postmenopausal osteoporotic women (- 3.18 ± 0.61) was also significantly lower than that of non osteoporotic women (- 0.56 ± 0.92) at p<; 0.05*. Serum IGF-1 level was correlated with BMD in postmenopausal osteoporotic women (r = 0.470, p = 0.001) as well as in postmenopausal non osteoporotic women (r = 0.346, p = 0.006) respectively. A decline of IGF-1 is one of the important mechanisms leading to the development of osteoporosis. Attempt should be made to identify a marker that not only changes earlier than BMD but also has some capacity to differentiate osteoporotic women with low bone mass from normal. IGF1 serves as a candidate.